- European regulators recommend rejection of Merck’s Covid-19 drug molnupiravir Endpoints News
- Europe’s CHMP advises against authorization of Merck’s Lagevrio FiercePharma
- Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator’s decision to recommend refusing authorization of their COVID antiviral MarketWatch
- EU regulator recommends against approval for Merck’s COVID pill for adults Reuters.com
- Merck/Ridgeback COVID-19 pill rejected in Europe (NYSE:MRK) Seeking Alpha
- View Full Coverage on Google News
Read More: European regulators recommend rejection of Merck’s Covid-19 drug molnupiravir –